Patient Rating:

No Rating Available?

Michael E. Engel, M.D., Ph.D., F.A.A.P.

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 662-4700 Primary Children's Hospital
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Bio

Michael Engel, MD, PhD, attended the Vanderbilt University School of Medicine in Nashville, TN. He completed his Pediatric residency training and subspecialty training in Pediatric Hematology/Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. He recently joined the faculty of the University of Utah School of Medicine and Primary Children's Medical Center as Assistant Professor in the Division of Pediatric Hematology/Oncology and as Adjunct Assistant Professor in the Department of Oncological Sciences of the Huntsman Cancer Institute.

Dr. Engel's clinical interests encompass hematologic and oncologic illness in children, adolescents and young adults, with an emphasis on hematologic malignancies including myeloid and lymphoid leukemias.

Dr. Engel's laboratory research interests involve the molecular machinery governing normal hematopoiesis and the molecular pathogenesis of acute leukemias, with a focus on alterations to the signaling machinery that govern cell growth and development. In the clinical domain, Dr. Engel is an active participant in clinical and translational research as a member of the Children's Oncology Group and as a leader within the Center for Children's Cancer Research of the Huntsman Cancer Institute.

As a member of the teaching faculty, Dr. Engel has a long-standing commitment to teaching and mentoring in both the clinical and laboratory domains. His teaching roles have involved learners at the pre- and post-doctoral levels and encompass both didactic and small group settings. He serves as Director of the Pediatric Hematology/Oncology Fellowship Program at the University of Utah and Primary Children's Medical Center.

Dr. Engel is a past recipient of a National Young Investigator award from the American Society of Pediatric Hematology/Oncology, a Ruth Kirschstein fellowship from the National Cancer Institute, a young investigator award from Alex's Lemonade Stand Pediatric Cancer Research Foundation, and served as a Hyundai Hope on Wheels Foundation Scholar. His research is currently supported by a Research Scholar Award from the St. Baldrick's Pediatric Cancer Research Foundation, research grants from CureSearch and Hope Street Kids foundations and a K08 Career Development Award from the National Institutes of Health. In the clinical setting, Dr. Engel is the recipient of a prestigious PRC Top Performer Award for 100th percentile patient satisfaction.

Board Certification and Academic Information

Academic Departments Pediatrics - Assistant Professor
Oncological Sciences - Adjunct Assistant Professor
Academic Divisions Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Ped Hematology-Oncology)
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Profile

Research Interests

  • Childhood Acute Leukemia
  • Hematopoiesis

Board Certification and Academic Information

Academic Departments Pediatrics - Assistant Professor
Oncological Sciences - Adjunct Assistant Professor
Academic Divisions Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Ped Hematology-Oncology)
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Office Locations

Academic Office Phone Number Academic Office Address
Huntsman Cancer Institute
Laboratory
2000 Circle of Hope
Salt Lake City, UT 84112
(801) 587-3882 Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112
Primary Children's Hospital
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Academic Bio

Michael Engel, MD, PhD, attended the Vanderbilt University School of Medicine in Nashville, TN. He completed his Pediatric residency training and subspecialty training in Pediatric Hematology/Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. He recently joined the faculty of the University of Utah School of Medicine and Primary Children's Medical Center as Assistant Professor in the Division of Pediatric Hematology/Oncology and as Adjunct Assistant Professor in the Department of Oncological Sciences of the Huntsman Cancer Institute (HCI). He is an HCI investigator and member of the Nuclear Control of Cell Growth and Differentiation program.

Dr. Engel's clinical interests encompass hematologic and oncologic illness in children, adolescents and young adults, with an emphasis on hematologic malignancies including myeloid and lymphoid leukemias.

Dr. Engel's laboratory research interests involve the molecular determinants of normal and malignant hematopoiesis, with a focus on alterations to the signaling machinery and gene expression programs that govern cell growth and development. In the clinical domain, Dr. Engel is an active participant in clinical and translational research as a member of the Children's Oncology Group.

As a member of the teaching faculty, Dr. Engel has a long-standing commitment to teaching and mentoring in both the clinical and laboratory domains. His teaching roles have involved learners at the pre- and post-doctoral levels and encompass both didactic and small group settings. Dr. Engel serves as the Pediatric hematology/oncology fellowship program director at the University of Utah and Primary Children's Hospital, and trainees supervised by him serve as faculty at academic medical centers throughout the United States. Grounded in his interests in mentoring and development of colleagues, Dr. Engel was selected to represent the University of Utah School of Medicine on the Council of Faculty and Academic Societies of the Association of American Medical Colleges.

Dr. Engel is a past recipient of a National Young Investigator award from the American Society of Pediatric Hematology/Oncology, a Ruth Kirschstein fellowship from the National Cancer Institute, a young investigator award from Alex's Lemonade Stand Pediatric Cancer Research Foundation, and served as a Hyundai Hope on Wheels Foundation Scholar. His research is currently supported by a Research Scholar Award from the St. Baldrick's Pediatric Cancer Research Foundation, research grants from CureSearch and Hope Street Kids foundations and a K08 Career Development Award from the National Institutes of Health. He is a member of the American Society of Hematology, the American Association for Cancer Research and its affiliated Pediatric Cancer Working Group, and the American Society of Pediatric Hematology/Oncology. In the clinical setting, Dr. Engel is the recipient of a prestigious PRC Top Performer Award, which recognizes physicians with patient satisfaction ratings in the 100th percentile nationally. In addition to his research and clinical duties, Dr. Engel is working with colleagues at the University of Utah and the Huntsman Cancer Institute to develop the Center for Children's Cancer Research.

Education

Education History

Type School Degree
Research Fellow Vanderbilt University Medical Center
Department of Biochemistry
Research Fellow
Fellowship Vanderbilt University Medical Center
Pediatric Hematology/Oncology
Clinical Fellow
Residency Vanderbilt University Medical Center
Pediatrics – Special Alternative Pathway Trainee
Resident
Professional Medical Vanderbilt University School of Medicine
Medical Scientist Training Program
M.D.
Doctoral Training Vanderbilt University School of Medicine
Medical Scientist Training Program
Ph.D.
Other Training Vanderbilt University School of Medicine
Medical Scientist Training Program
Undergraduate Purdue University, West Lafayette Campus
Biology
B.S.

Publications

Selected Provider Publications

Journal Article

  1. Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma.Mixon BA, Eckrich MJ, Lowas S, Engel ME (2013). Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol, 35(4), e163-6.
  2. Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters.Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS (2012). Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. PLoS One, 7(12), e51205.
  3. Fagan E, Slone J, Shoemaker A, Black J, Berlin J, Engel ME (April 2012). Neuroendocrine carcinoma in an adolescent with hypercortisolemia. J Pediatr Hematol Oncol, 34(3), 117-119.
  4. Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification.Engel ME, Nguyen HN, Mariotti J, Hunt A, Hiebert SW (2010). Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. Mol Cell Biol, 30(7), 1852-63.
  5. Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation.Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, Engel M, Hiebert SW (2008). Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Mol Cell Biol, 28(20), 6234-47.
  6. Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution.Frangoul H, Wills M, Crossno C, Engel M, Domm J (2007). Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant, 11(8), 942-4.
  7. Matched unrelated bone marrow transplantation with reduced-intensity conditioning for leukocyte adhesion deficiency.Engel ME, Hickstein DD, Bauer TR Jr, Calder C, Manes B, Frangoul H (2006). Matched unrelated bone marrow transplantation with reduced-intensity conditioning for leukocyte adhesion deficiency. Bone Marrow Transplant, 37(7), 717-8.
  8. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell, 12(1), 27-36.
  9. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription.Engel ME, McDonnell MA, Law BK, Moses HL (1999). Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem, 274(52), 37413-20.
  10. RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation.Engel ME, Datta PK, Moses HL (1998). RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation. J Biol Chem, 273(16), 9921-6.
  11. Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes.Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh MB (1998). Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology, 139(8), 3620-8.
  12. Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha.Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL (1995). Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha. J Biol Chem, 270(50), 29628-31.
  13. High-level secretion of biologically active aprotinin from the yeast Pichia pastoris.Vedvick T, Buckholz RG, Engel M, Urcan M, Kinney J, Provow S, Siegel RS, Thill GP (1991). High-level secretion of biologically active aprotinin from the yeast Pichia pastoris. J Ind Microbiol, 7(3), 197-201.

Review

  1. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation.Engel ME, Datta PK, Moses HL (1998). Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. [Review]. J Cell Biochem Suppl, 30-31, 111-22.

Book Chapter

  1. Engel ME, and Hiebert SW (2010). Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. In Lalitha Nagarajan, PhD (Ed.), Cancer Treatment and Research (Acute Myelogenous Leukemia-Genetics, Biology and Therapy, 145, pp. 127-147). New York: Springer.

Abstract

  1. Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S and Engel ME (2013). Lysine Specific Demethylase-1 inhibition as a therapeutic strategy that leverages the requirement for Growth Factor Indepndence-1 in Notch-driven T-ALL [Abstract]. American Association for Cancer Research-Pediatric Oncology Working Group--Pediatric Cancer at the Crossroads-Translating discovery into improved outcomes.
  2. Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S, Maese L and Engel ME (2013). Notch alters sumoylation to govern GFI1 protein stability and support its transcriptional repression function [Abstract]. American Society of Hematology National Meeting, New Orleans, LA.
  3. Andrade D, Singe J, Bareyan D, McClellan D, Lucente H, Chandrasekharan M, and Engel ME (2013). Notch and PIAS3 differentially regulate sumoylation of GFI1 to modulate transcriptional repression [Abstract]. AACR National Meeting, Washington, DC.
  4. Andrade D, Maese L, Singer J, Bareyan D, McClellan D, Lucente H, Quinton R, Chandrasekharan M, Liu F, and Engel ME (2013). Sumoylation regulates the half-life of Growth Factor Independence (GFI)-1 to modulate transcriptional repression [Abstract]. ASPHO National Meeting, Miami, FL.
  5. Andrade DL, Bareyan D, Singer J, Quinton R, Engel ME (2012). Regulation of GFI1 proteins by Notch intracellular domains [Abstract]. American Association for Cancer Research National Meeting.
  6. Mangrum DS, Shams S, Downie J, von Schwelder U, Rodic V, Engel ME, Barnette P, Frazer JK, Trede N, Pei D, Cheng C, Mullighan C, Yang J, Miles R, Schiffman JD (2011). Focal 22q11.22 loss combined with IKZF1 alterations predict very poor outcome in childhood acute lymphoblastic leukemia [Abstract]. American Society of Hematology National Meeting, San Diego, CA.
  7. Mariotti J, Nguyen HN and Engel ME (2010). Structure—function relationships between RUNX1-MTG fusion proteins and core components of the Notch transcription complex [Abstract]. American Association for Cancer Research National Meeting. Washington, DC.
  8. Chadalavada N, Nguyen HN, Mariotti J and Engel ME (2009). GFI1B interacts with the intracellular domain of Notch1 [Abstract]. Vanderbilt University School of Medicine, Center for Scientific Outreach. Siemens Competition in Math, Science and Technology-Semifinalist. Nashville, TN.
  9. Engel ME, Nguyen HN, Mariotti J, Hunt A and Hiebert SW (2009). Myeloid translocation gene (MTG)-16 binds intracellular domains of Notch receptors to coordinate Notch-dependent cell fate specification [Abstract]. American Society of Hematology National Meeting. Symposium on regulation of gene transcription in hematopoiesis. New Orleans, LA.
  10. Engel ME, Nguyen HN, Mariotti J, Hunt A, and Hiebert SW (2009). Regulation of the canonical Notch transcription complex by Myeloid Translocation Gene-16 in hematopoietic cell fate specification [Abstract]. FASEB summer research conference-Hematologic Malignancies. Saxtons River, VT.
  11. Williams C, Moore AC, Amann J, Engel ME, Ellis T, Whitehead R, and Hiebert SW (2007). A role for MTGR1 in intestinal epithelial migration and repair [Abstract]. American Gastrointestinal Association National Meeting. Washington, DC.
  12. Engel ME and Hiebert SW (2007). MTG16-mediated transcriptional repression and NCoR interaction are regulated by A-kinase [Abstract]. American Association for Cancer Research National Meeting. Minisymposium-Repression of Gene Expression. San Diego, CA.
  13. Engel ME, Hunt A, Ice RJ, and Hiebert SW (2006). Phosphorylation-mediated control of gene expression by the myeloid translocation gene protein, MTG16: Implications for hematopoietic stem cell self renewal and leukemogenesis [Abstract]. American Society of Pediatric Hematology/Oncology National Meeting. Presidential Symposium. Francisco, CA.
  14. Engel ME, Ice RJ, Hunt AH, and Hiebert SW (2006). Phosphorylation-mediated control of transcriptional repression by the myeloid translocation gene protein, MTG16 [Abstract]. American Association for Cancer Research National Meeting. Washington, DC.
  15. Williams C, Engel ME, Ellis T, Martinez A, and Hiebert SW (2006). Susceptibility to DSS induced colitis in MTGR1 and MTG16 deficient mice [Abstract]. American Gastrointestinal Association Institute Conference on Stem Cells in Gastrointestinal Development, Regeneration and Neoplasia. Tysons Corner, VA.
  16. Engel ME, Ice RJ, Hiebert, SW (2005). Post-translational modifications of the Myeloid Translocation Gene protein, Eto2 [Abstract]. FASEB Summer Research Conference-Hematopoietic Malignancies. Saxtons River Vermont.
  17. Engel ME, and Moses HL (1998). The Role of Rho Proteins in TGF- ß Signaling [Abstract]. FASEB Summer Research Conference-Receptors and Signal Transduction. Copper Mountain, CO.
  18. Brierly R, Buckholz R, Engel ME, DAndrea M, Holtz G, Kinney M, Provow S, Siegel R, Thill G, Vedvick T, Velicelebi G, and Wondrack L (1991). High Level Secretion of Recombinant Insulin-Like Growth Factor-1 from the Methylotropic Yeast Pichia pastoris [Abstract]. International Symposium on Somatomedins.

Other

  1. The enemy within: dormant retroviruses awaken.Engel ME, Hiebert SW (2010). The enemy within: dormant retroviruses awaken. Nat Med (16(5), pp. 517-8). United States.
  2. Engel ME (1999). Rho GTP-Binding Proteins and the C-Jun N-Terminal Kinase Cascade. Ph.D. Thesis. Vanderbilt University.

Patent

  1. Engel ME, Vedvick T, Urcan M, Buckholz R, and Kinney J (1993). Expression System for Bovine Pancreatic Trypsin Inhibitor (BPTI/Aprotinin) Peptides. U.S. Patent No. US5258302. Washington, D.C.:U.S. Patent and Trademark Office.

Poster

  1. Quinton R, Bareyan D, Andrade DL, Singer J, McLellan D, Engel ME (2011). Myeloid Translocation Gene (MTG) 16 and the Notch pathway in in vitro erythropoiesis. Poster session presented at Eccles Institute of Human Genetics, Salt Lake City, UT.

Clinical Trials

Video & News